88 related articles for article (PubMed ID: 18399831)
1. A novel murine model of allogeneic vaccination against renal cancer.
Havranek EG; Labarthe MC; Ward S; Anderson CJ; Whelan MA; Pandha H
BJU Int; 2008 May; 101(9):1165-9. PubMed ID: 18399831
[TBL] [Abstract][Full Text] [Related]
2. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.
Rossi GR; Mautino MR; Awwad DZ; Husske K; Lejukole H; Koenigsfeld M; Ramsey WJ; Vahanian N; Link CJ
J Immunother; 2008; 31(6):545-54. PubMed ID: 18528300
[TBL] [Abstract][Full Text] [Related]
4. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma.
Fujioka T; Hasegawa M; Ishikura K; Matsushita Y; Sato M; Tanji S
J Urol; 1998 Jul; 160(1):247-51. PubMed ID: 9628658
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
7. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
8. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models.
Cho JA; Lee YS; Kim SH; Ko JK; Kim CW
Cancer Lett; 2009 Mar; 275(2):256-65. PubMed ID: 19036499
[TBL] [Abstract][Full Text] [Related]
9. Whole tumor cell vaccine with irradiated S180 cells as adjuvant.
Li J; King AV; Stickel SL; Burgin KE; Zhang X; Wagner TE; Wei Y
Vaccine; 2009 Jan; 27(4):558-64. PubMed ID: 19027812
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Mulders P
Eur Urol; 2009 Jul; 56(1):132-3. PubMed ID: 18550266
[No Abstract] [Full Text] [Related]
13. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
14. Cell based cancer vaccines: regulatory and commercial development.
Copier J; Ward S; Dalgleish A
Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
[TBL] [Abstract][Full Text] [Related]
15. Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Novara G
Eur Urol; 2009 Jul; 56(1):131-2. PubMed ID: 18550268
[No Abstract] [Full Text] [Related]
16. Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases.
Fifis T; Lam I; Lin D; Malcontenti-Wilson C; Christophi C; Loveland B
Vaccine; 2008 Jan; 26(2):241-9. PubMed ID: 18069095
[TBL] [Abstract][Full Text] [Related]
17. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
[TBL] [Abstract][Full Text] [Related]
18. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer.
Bird RC; Deinnocentes P; Lenz S; Thacker EE; Curiel DT; Smith BF
Vet Immunol Immunopathol; 2008 Jun; 123(3-4):289-304. PubMed ID: 18423623
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of human renal cancer cell lines and autologous normal kidney short term cultures.
Schattka S; Decken K; Schmitz-Dräger B; Ackermann R; Ebert T
Investig Urol (Berl); 1994; 5():35-41. PubMed ID: 7719318
[No Abstract] [Full Text] [Related]
20. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
